Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements

Audio By Carbonatix

LAKE FOREST, Ill.--(BUSINESS WIRE)--Jan 12, 2026--

Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with all applicable listing requirements.

As of January 12, 2026, Nasdaq has determined that Assertio has regained compliance with the Minimum Bid Price Rule, which requires the Company’s common stock maintains a minimum bid price of $1.00 per share for a minimum of ten consecutive days, and that the matter is now closed.

Mark Reisenauer, Chief Executive Officer of Assertio: “We are pleased to have regained compliance with applicable listing requirements. Importantly, we accomplished this efficiently with the successful completion of our December 2025 reverse stock-split, while preserving capital allocation flexibility.”

About Assertio
Assertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients by marketing products in oncology, neurology, and pain management.

Forward Looking Statements

Statements in this communication that are not historical facts are forward-looking statements that reflect Assertio’s current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio, including statements about the Reverse Split. All statements other than historical facts may be forward-looking statements and can be identified by words such as “anticipate,” ‘believe,” “could,” “design,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “imply,” “intend,” “may,” “objective,” “opportunity,” “outlook,” “plan,” “position,” “potential,” “predict,” “project,” “prospective,” “pursue,” “seek,” “should,” “strategy,” “target,” “would,” “will,” “aim” or other similar expressions that convey the uncertainty of future events or outcomes are used to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of Assertio.

Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks are more fully described in Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC and in other filings Assertio makes with the SEC from time to time. Investors and potential investors are urged not to place undue reliance on forward-looking statements in this communication, which speak only as of this date. While Assertio may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by applicable law. Nothing contained herein constitutes or will be deemed to constitute a forecast, projection or estimate of the future financial performance or expected results of Assertio.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260112434688/en/

CONTACT: Investor Contact

Longacre Square Partners

[email protected]

KEYWORD: ILLINOIS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: MARKETING PHARMACEUTICAL COMMUNICATIONS HEALTH

SOURCE: Assertio Holdings, Inc.

Copyright Business Wire 2026.

PUB: 01/12/2026 04:15 PM/DISC: 01/12/2026 04:17 PM

http://www.businesswire.com/news/home/20260112434688/en